Psychotropic Drug Use- July/September 2010


Measure10_1_Overall: Prevalence of Antipsychotic Use, in the Absence of Psychotic or Related Conditions: Overall - Residents receiving antipsychotics on the target assessment.


Measure10_1_HI: Prevalence of Antipsychotic Use, in the Absence of Psychotic or Related Conditions: High Risk - Residents who exhibit both cognitive impairment and behavior problems on the most recent assessment are considered high risk to receive antipsychotic medication(s).


Measure10_1_LO: Prevalence of Antipsychotic Use, in the Absence of Psychotic or Related Conditions: Low Risk - Low risk is defined as all other residents who are not high risk. Residents with one or more psychotic disorders are excluded from this measure.


Measure10_2: Prevalence of Antianxiety/Hypnotic Use - Residents who received antianxiety or hypnotics on the target assessment.


Measure10_3: Prevalence of Hypnotic Use More Than Two Times in Last Week - Residents who received hypnotics more than 2 times in the last week on the target assessment.


Figures indicate percentage across state of residents exceeding Quality Measure/Quality Indicator trigger.

State Measure10_1_Overall Measure10_1_HI Measure10_1_LO Measure10_2 Measure10_3
National 18.5%  39.4%  15.6%  23.4%  5.5% 
AK 11.8%  44.0%  8.2%  20.5%  4.4% 
AL 15.7%  37.2%  13.9%  27.7%  6.9% 
AR 18.2%  37.9%  16.2%  20.7%  3.6% 
AZ 18.9%  46.3%  15.4%  21.3%  5.3% 
CA 16.1%  44.6%  13.4%  20.7%  6.6% 
CO 18.1%  34.2%  15.2%  18.7%  3.3% 
CT 23.5%  48.2%  21.1%  23.3%  5.4% 
DC 13.6%  35.9%  11.7%  12.1%  3.3% 
DE 18.5%  44.5%  15.8%  23.7%  4.5% 
FL 12.0%  31.5%  10.2%  27.6%  8.4% 
GA 22.8%  41.8%  18.3%  24.7%  6.1% 
HI 12.3%  33.3%  9.7%  10.7%  3.8% 
IA 19.4%  42.3%  15.0%  24.5%  3.1% 
ID 22.2%  47.9%  18.4%  23.5%  6.0% 
IL 22.6%  37.9%  19.4%  21.8%  3.9% 
IN 19.2%  42.1%  17.5%  23.7%  5.3% 
KS 20.5%  38.1%  17.3%  21.6%  3.8% 
KY 19.9%  40.2%  17.6%  31.9%  6.9% 
LA 26.2%  46.1%  23.8%  28.6%  10.8% 
MA 20.2%  36.6%  16.9%  19.7%  2.0% 
MD 15.3%  41.6%  13.2%  16.0%  3.5% 
ME 22.9%  38.1%  18.7%  24.4%  3.4% 
MI 12.6%  31.4%  10.4%  18.4%  2.1% 
MN 13.4%  27.9%  9.9%  15.5%  1.9% 
MO 21.5%  44.4%  18.5%  25.1%  5.1% 
MS 21.4%  41.7%  19.4%  25.0%  8.2% 
MT 17.7%  35.2%  14.7%  20.0%  4.8% 
NC 17.3%  36.7%  14.9%  30.2%  7.8% 
ND 14.8%  33.0%  11.9%  22.4%  3.0% 
NE 19.2%  39.7%  15.4%  22.6%  4.2% 
NH 18.8%  42.5%  16.1%  21.5%  3.0% 
NJ 15.5%  41.5%  12.8%  19.6%  5.3% 
NM 16.8%  37.8%  13.6%  22.5%  6.7% 
NV 15.9%  34.8%  14.3%  27.4%  10.3% 
NY 18.6%  43.4%  15.4%  15.5%  3.7% 
OH 19.0%  37.1%  15.3%  25.8%  5.4% 
OK 24.3%  50.4%  21.5%  32.5%  12.0% 
OR 18.5%  38.4%  15.9%  19.1%  3.5% 
PA 16.2%  36.8%  14.2%  21.8%  4.0% 
PR 75.0%  0.0%  75.0%  100.0%  0.0% 
RI 23.0%  47.7%  19.9%  17.4%  2.9% 
SC 16.0%  35.5%  13.1%  27.5%  6.8% 
SD 16.4%  33.7%  12.6%  20.0%  3.1% 
TN 21.5%  42.6%  19.2%  33.9%  8.4% 
TX 20.0%  39.0%  17.5%  27.0%  8.9% 
UT 23.8%  43.8%  18.8%  35.0%  11.1% 
VA 18.2%  41.0%  15.1%  25.6%  5.5% 
VI 0.0%  0.0%  0.0%  0.0%  0.0% 
VT 19.9%  38.7%  14.9%  18.2%  4.1% 
WA 16.3%  37.4%  13.1%  18.7%  3.2% 
WI 16.1%  37.8%  12.9%  20.8%  2.5% 
WV 17.5%  38.2%  14.7%  25.9%  3.1% 
WY 16.4%  38.2%  12.2%  20.8%  3.5% 

Source: MDS National Quality Indicator System.